A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab



Status:Recruiting
Conditions:Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - 65
Updated:6/22/2018
Start Date:May 8, 2018
End Date:December 31, 2019
Contact:Clinical Operations
Email:PNHTrialInquiries@achillion.com
Phone:+1 203-752-5577

Use our guide to learn which trials are right for you!

A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

To determine the effectiveness of ACH-0144471 in improving anemia when given with eculizumab
for 24 weeks in patients with PNH.

The purpose of this study is to determine the effectiveness of ACH-0144471 in improving
anemia, as measured by increased blood hemoglobin, when given with eculizumab (a drug
commonly used for treatment of PNH) for 24 weeks in patients with PNH.

Key Inclusion Criteria:

- Diagnosed with PNH

- 18 to 65 years of age

- Have received at least one RBC transfusion within last 12 weeks

- Anemia with adequate reticulocytosis

- Must be on a stable regimen of eculizumab

- Platelet count ≥ 40,000/μL without the need for platelet transfusions

- Documentation of vaccination for N. meningitidis, H. influenza, and S. pneumoniae or
willingness to receive vaccinations based on local guidelines

- Willingness to receive antibiotic prophylaxis

- Female participants must use highly effective birth control to prevent pregnancy
during the clinical trial and for 30 days after their last dose of study drug.

- Male participants must use a highly effective birth control with a female partner to
prevent pregnancy during the clinical trial and for 90 days after the last dose of
study drug.

Key Exclusion Criteria:

- Current evidence of bone marrow failure or aplastic anemia requiring treatment

- History of a major organ transplant or hematopoietic stem cell/marrow transplant

- Received another investigational agent within 30 days or 5 half-lives of the
investigational agent prior to study entry, whichever is greater

- Documented C5 mutations

- Known or suspected complement deficiency

- Contraindication to any of the required vaccinations

- Active bacterial infection or clinically significant active viral infection, a body
temperature >38°C, or other evidence of infection

- History of meningococcal infection, or a first-degree relative or household contact
with a history of meningococcal infection

- History of hypersensitivity reactions to commonly used antibacterial agents

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
We found this trial at
2
sites
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Jaroslaw Maciejewski, M.D., Ph.D.
Phone: 216-445-1019
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Baltimore, Maryland 21287
Principal Investigator: Robert Brodsky, M.D.
Phone: 410-502-2547
?
mi
from
Baltimore, MD
Click here to add this to my saved trials